EHA 2014

Stopping TKIs Safe after Deep Molecular Response

Robert Osborne

August 2014, Vol 5, No 6 - EHA 2014

Milan, Italy—More than 60% of patients with chronic myeloid leukemia (CML) were free of relapse 6 months after stopping tyrosine kinase inhibitor (TKI) therapy that led to deep molecular remission, according to the interim results from an ongoing trial reported by Susanne Saussele, MD, of Universitätsmedizin Mannheim, Germany, at the 2014 European Hematology Association meeting. [ Read More ]